The Zunzunwala family -backed IKS health views a block deal worth 500 crore; Stock 4% slides

The tech-powered healthcare service firm, supported by the Zunzunwala family, represents 1.75% of the company’s equity, changing hands to a block deal worth Rs 499 crore on Thursday. After the transaction, the stock on BSE was 7.7% intraday to Rs 1,640.55.

According to the CNBC-TV18 report, the average of the stocks was Rs. Traders were traded at a price of 1,659, with a floor price of Rs 1,650-a 2.6% discount on a closed price of Rs 1,695 on Wednesday. The identity of buyers and sellers was not officially disclosed, though sources told CNBC-TV18 that many individual investors are likely to sell.

The Block Balock Deal came on Wednesday a day after the end of the six -month IPO L -C -in period of IKS Health. With a l-in withdrawal, 10.5 million shares are eligible for a business worth about $ 20 billion. Market participants were expecting such a deal.

The stock has now dropped more than 12% in two sessions and its post-listing high is Rs.

Promoter group and IPO wind IKS Health has been endorsed by the Jhunjhunwala family by three discretionary trusts-Nistha, Aryavir and Aryaman-March 2025 holds 16.37% of the company by 2025. Rekha Zunjhunwala also accounts for 0.23%, but does not participate in selling IPOs.

Living events

      When the company listed on December 19, 2024, the Zunzunwala family has reported a surprising 530X return on their investment. Rs. The 2,500 crore IPO was overscributed 53 times and entered the NSE at Rs 1,900, which is 43% premium than the issue of Rs 1,329.

      As part of the Sale Fur-Four-Sale, three family trusts shared. No new capital is included in the IPO.

      Business snapshot IKS Health, which is known as Formal Pacharus, is known as the Solutions of the Inventurus Jnowledge, provides a care -enabled platform for physician enterprise in the US, Canada and Australia Strallia, in which the US. Primary focus is on the market. It serves more than 778 healthcare organizations, including high-profile clients such as Mass General Brigg Inc., Texas Health Care PLC and GI Alliance Management.

      The company has recorded financial growth in recent years, with revenue of EBITDA and 8.1.1%, 8.3%, .3..3%and 8.1.1%, respectively between FY 22 and FY 24. For the six months ended September 2024, the revenue from the operation has doubled to 1,283 crore, while the net profit increased by fresh to 208 crore.

      Now, with the first wave of L -C -in period and sale, market observers are eagerly monitoring more out by early investors or promoters in the next week.

      (Connection: The recommendations, suggestions, views and views of the experts are their own. This does not represent opinions of economic time)

      (Now you can subscribe to our Etmarkets WhatsApp channel)

      Share This Article
      Leave a Comment

      Leave a Reply

      Your email address will not be published. Required fields are marked *

      Exit mobile version